Patents by Inventor Raymond J. Paxton

Raymond J. Paxton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN
    Publication number: 20130023647
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: September 10, 2012
    Publication date: January 24, 2013
    Inventors: Steward D. Lyman, Kirk P. Van Ness, Raymond J. Paxton
  • MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN
    Publication number: 20110230637
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: June 1, 2011
    Publication date: September 22, 2011
    Applicant: IMMUNEX CORPORATION
    Inventors: Stewart D. LYMAN, Kirk P. VAN NESS, Raymond J. PAXTON
  • Nucleic acid encoding modified human thymic stromal lymphopoietin
    Patent number: 7973151
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: July 5, 2011
    Assignee: Amgen Inc.
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond J. Paxton
  • Antagonists of interleukin-15
    Patent number: 7763434
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: July 27, 2010
    Assignee: Immunex Corporation
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN
    Publication number: 20100167393
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: March 12, 2010
    Publication date: July 1, 2010
    Applicant: IMMUNEX CORPORATION
    Inventors: Stewart D. LYMAN, Kirk P. VAN NESS, Raymond J. PAXTON
  • Modified human thymic stromal lymphopoietin
    Patent number: 7709217
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: May 4, 2010
    Assignee: Immunex Corporation
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond J. Paxton
  • Antagonists of Interleukin-15
    Publication number: 20100015723
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
    Type: Application
    Filed: May 23, 2007
    Publication date: January 21, 2010
    Applicants: Amgen Inc., IMMUNEX CORPORATION
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Modified human thymic stromal lymphopoietin
    Publication number: 20080145866
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: October 30, 2007
    Publication date: June 19, 2008
    Applicant: Immunex Corporation
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond J. Paxton
  • Modified human thymic stromal lymphopoietin
    Patent number: 7288633
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: October 30, 2007
    Assignee: Immunex Corporation
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond J. Paxton
  • Antagonists of interleukin-15
    Patent number: 7235240
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: June 26, 2007
    Assignee: Amgen Inc.
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Antagonists of interleukin-15
    Patent number: 7067132
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: June 27, 2006
    Assignee: Immuner Corp.
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Antagonists of interleukin-15
    Patent number: 7008624
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: March 7, 2006
    Assignee: Immunex Corporation
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Antagonists of interleukin-15
    Publication number: 20040253587
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&agr;-subunit and that are incapable of transducing a signal through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
    Type: Application
    Filed: November 6, 2002
    Publication date: December 16, 2004
    Applicant: Immunex Corporation
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Antagonists of interleukin-15
    Patent number: 6177079
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&agr;-subunit and that are incapable of transducing a signal through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the B- or &ggr;subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed. including treating allograft rejection and graft-versus-host disease.
    Type: Grant
    Filed: November 20, 1998
    Date of Patent: January 23, 2001
    Assignee: Immunex Corporation
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Antagonists of interleukin-15
    Patent number: 6168783
    Abstract: Antagonists of mammalian interleukin-15 (“IL-l5”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&agr;-subunit and that are incapable of transducing a signal through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: January 2, 2001
    Assignee: Immunex Corporation
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Antagonists of interleukin-15
    Patent number: 6165466
    Abstract: Antagonists of mammalian interleukin-15 ("IL-15") are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R.alpha.-subunit and that are incapable of transducing a signal through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed including treating allograft rejection and graft-versus-host disease.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: December 26, 2000
    Assignee: Immunex Corporation
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Antagonists of interleukin-15
    Patent number: 6013480
    Abstract: Antagonists of mammalian interleukin-15 ("IL-15") are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R.alpha.-subunit and that are incapable of transducing a signal through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: January 11, 2000
    Assignee: Immunex Corporation
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Antagonists of interleukin-15
    Patent number: 5795966
    Abstract: Antagonists of mammalian interleukin-15 ("IL-15") are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R.alpha.-subunit and that are incapable of transducing a signal through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
    Type: Grant
    Filed: February 22, 1995
    Date of Patent: August 18, 1998
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton